+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating a medicine called survodutide in adults aged 18 and older who have confirmed non-alcoholic steatohepatitis NASH or metabolic-associated steatohepatitis MASH with cirrhosis, and a body mass index BMI of 27 kgm2 or higher, or 25 kgm2 for Asian participants. The study aims to find out if survodutide helps improve liver function and related health outcomes in these individuals. People with other chronic liver diseases or high alcohol intake are not eligible to participate. Participants are randomly assigned to one of two groups one group receives once-weekly injections of survodutide, and the other group receives a placebo injection that looks the same but contains no medicine. Both groups receive counseling to encourage dietary changes and regular exercise. The study is double-blinded, meaning neither participants nor doctors know which treatment is given. The trial lasts up to 4 and a half years, with visits either in person or via video calls scheduled every 2, 4, or 6 weeks for about 17 months, then every 3 months afterwards. Throughout the study, researchers monitor participants health, body weight, and any side effects. They use imaging methods to measure liver parameters and collect symptom questionnaires. The main outcome measured is the time until serious liver-related events occur, such as liver transplant or worsening liver function. Secondary outcomes include changes in liver fibrosis, body weight, blood sugar control, liver stiffness, and other health markers. This thorough monitoring helps compare the effects of survodutide to placebo over the long term.

Age: 18Years +All GendersPhase 3
447 locations
E

Actively Recruiting

Researchers are studying adults aged 18 and older who live with obesity and have a liver disease known as non-alcoholic steatohepatitis NASH or metabolic associated steatohepatitis MASH with moderate or advanced liver fibrosis. The study aims to evaluate whether a medicine called survodutide can improve liver function in people with these conditions. It is a Phase III, randomized, double-blind, placebo-controlled trial conducted at multiple centers. Participants are randomly assigned to one of two groups one receives weekly injections of survodutide, and the other receives placebo injections that look the same but contain no medicine. The survodutide dose is gradually increased until reaching the target dose. All participants receive counseling on diet and exercise. The study includes two parts the first focuses on the effect of survodutide on NASH and fibrosis over one year, and the second assesses its long-term safety and effectiveness over up to seven years. Participants stay in the study for up to seven years, attending regular visits either in person or remotely via video call. Visits occur every two weeks initially, then every four to six weeks, and later every three months. Doctors monitor health, record any side effects, and measure body weight and digestive symptoms. Liver assessments include imaging and biopsies at selected visits. Participants also complete questionnaires about symptoms and quality of life. Researchers compare results between the groups to assess the medicines effects on liver health and related outcomes.

Age: 18Years +All GendersPhase 3
532 locations
L

Actively Recruiting

Researchers are evaluating the performance of the Gynecare TVT ABBREVO4 Continence System in women undergoing mid-urethral sling surgery to treat Stress Urinary Incontinence SUI. This observational, post-market clinical study focuses on long-term follow-up to assess the systems impact on continence over approximately 5 to 10 years after surgery. Participants undergo surgical treatment for SUI using the Gynecare TVT ABBREVO4 device as part of standard care. There is no additional intervention in the study beyond the usual surgical procedure and clinical care. The study follows participants from the time of surgery through long-term follow-up lasting about 10 years. During the study, participants will be monitored with assessments including the Cough Stress Test CST to evaluate continence status, patient-reported improvement measures, urinary incontinence questionnaires, sexual function questionnaires, and pain rating scales. Follow-up involves regular evaluations through the study completion date to track outcomes and safety over the long term.

Age: 21Years +FEMALE
4 locations
O

Actively Recruiting

This research aims to understand how thyroidectomy removal of the thyroid gland complications may differ depending on the thyroid hormone levels before surgery in patients with Graves disease or Amiodarone-induced thyrotoxicosis AIT. It focuses on whether patients with different thyroid metabolic statescontrolled normal hormone levels or uncontrolled elevated hormone levelshave similar rates of complications such as nerve damage, hypoparathyroidism, bleeding, or severe heart events during and after surgery. The study is observational and uses data collected in the EUROCRINE registry from multiple centers in Europe. Patients who undergo thyroidectomy for Graves disease or AIT are grouped based on their hormone levels before surgery, using free triiodothyronine fT3 and free thyroxine fT4 tests taken within one week prior to surgery. The study does not alter the surgery or treatment methods. Data are collected prospectively through the EUROCRINE registry and an additional module for study-specific routine data. The study plans to include about 25 centers over two years and will record details such as surgery duration, blood loss, medications, monitoring techniques, hospital stay, and any complications. Participants will provide informed consent, and their usual surgical care is not changed. Researchers will track outcomes from the day of surgery through an average of two years, including complications and recovery. Data include clinical information, operative details, and postoperative follow-up. The study aims to help refine surgical guidelines and determine if waiting for normal thyroid levels before surgery is necessary, potentially speeding up treatment and reducing risks and costs for patients.

Age: 18Years +All Genders
15 locations